Our previous studies demonstrated that AAV-mediated expression of glucocerebrosidase in the CNS of mice with both pre- and post-symptomatic Gaucher disease was efficacious at reducing α-synuclein accumulation and reversing the associated cognitive impairment (26). This evidence concerns the gene GBA1 and Gaucher disease.